

Product Manual

产品说明书

Cat.No.T:

PC78797

CAS No. :

301836-41-9

Formula:

C22H16N4O3

Molecular Weight:

384.39

Storage:

Store under nitrogen,Keep away from moisture,Store at low temperature

Pure form: -20°C for 3 years | In solvent: -80°C for 1 year

Description:

SB-431542 is an inhibitor of ALK5/TGF- β type I Receptor (IC₅₀=94 nM) and is selective. SB 431542 also has inhibitory activity against ALK4 and ALK7 but not other proteins. SB 431542 can be used for induced differentiation of stem cells.

Targets(IC50):

Apoptosis,ALK,TGF-beta/Smad

In vitro:

METHODS: Human renal cell 293T, human colon cancer-derived non-tumorigenic cell FET, and human lung adenocarcinoma cell A549 were treated with SB-431542 (2-10 μ M) and TGF- β 1 (12.5 ng/mL) for 1 h. The expression levels of the target proteins were detected by Western Blot.

RESULTS: TGF- β 1 induced the complex formation between Smad2/3 and Smad4, and SB-431542 blocked the complex formation by blocking TGF- β -induced phosphorylation and Smad2/3 activation in a dose-dependent manner. [1]

METHODS: Human glioblastoma cells D54MG were treated with SB-431542 (1-10 μ M) for 24 h, and cell migration was detected by Transwell.

RESULTS: SB-431542 inhibited TGF- β RI signaling and blocked cell migration of D54MG cells in a concentration-dependent manner. [2]

METHODS: Human pluripotent stem cells hESCs were cultured in KSR medium containing SB-431542 (10 nM) and Noggin (500 ng/mL) for 11 days, and cell differentiation was detected using Immunofluorescence.

RESULTS: Neural induction was monitored by the expression of PAX6, an early marker of neuroectodermal differentiation. Combined treatment with Noggin and SB-431542 significantly increased the efficiency of neural induction to more than 80% of the total cells compared to less than 10% of PAX6+ cells when Noggin or SB-431542 were used alone. [3]

In vivo:

METHODS: To test the antitumor activity in vivo, SB-431542 (10 mg/kg in 20% DMSO/80% corn oil) was intraperitoneally injected three times a week for four weeks into Balb/c mice bearing mouse mammary cancer tumor 4T1.

RESULTS: SB-431542 significantly inhibited lung metastasis of 4T1 mammary tumors. [4]

METHODS: To investigate the treatment of tendon injuries, SB-431542 (10 mg/kg) was injected intraperitoneally into a C57B/6J mouse model with massive rotator cuff tears once daily for two or six weeks.

RESULTS: Inhibition of TGF- β 1 signaling by SB-431542 reduced fibrosis, fat infiltration, and muscle weight loss. SB-431542 treatment reduced the number of FAPs in the injured muscle by promoting apoptosis of fibro/adipogenic progenitor cells (FAPs), which are an important cellular source of fibrosis and fat infiltration in the rotator cuff muscle. [5]

Kinase Assay:

Kinase assays were performed with 65 nM GSTALK5 and 184 nM GST-Smad3 in 50 mM HEPES, 5 mM MgCl₂, 1 mM CaCl₂, 1 mM dithiothreitol, and 3 M ATP. Reactions were incubated with 0.5 μ Ci of [³³P] γ ATP for 3 h at 30°C. Phosphorylated protein was captured on P-81 paper, washed with 0.5% phosphoric acid, and counted by liquid scintillation. Alternatively, Smad3 or Smad1 protein was also coated onto FlashPlate Sterile Basic Microplates. Kinase assays were then performed in FlashPlates with same assay conditions using either the kinase domain of ALK5 with Smad3 as a substrate or the kinase domain of ALK6 (BMP receptor) with Smad1 as substrate. Plates were washed three times with phosphate buffer and counted by TopCount [2].

Cell Research:

A498 cells were seeded at 5,000 to 10,000 cells/well in 96-well plates. The cells were serum-deprived for 24 h and then treated with compounds for 48 h to assess the cellular toxicity. Cell viability is determined by incubating cells for 4 h with XTT labeling and electron coupling reagent. Live cells with active mitochondria produce an orange colored product, formazan, which is detected using a plate reader at between 450 nm and 500 nm with a reference wavelength greater than 600 nm. The absorbance values correlate with the number of viable cells [2].

Animal Research:

BALB/c mice received intraperitoneal (i.p.) injections of colon-26 tumor cells. Three days after tumor cell inoculation, SB-431542 (1 μ M solution, 100 μ l/animal) or vehicle alone was directly injected into the peritoneal cavity. CTL activities were measured by a standard 4 h ⁵¹Cr release assay after culturing spleen cells with γ -irradiated tumor cells for five days in the absence of added growth factors. In vitro experiments, cell lysate of HLA-A*2402 positive gastric cancer cell line, OCUM-8, was incubated with human DC cultures for 4 h. After washing extensively, PBMCs obtained from the same volunteer as DCs were incubated for 7 days and measured CTL activity by ⁵¹Cr release assay. NK activity was tested using ⁵¹Cr release assay against K562 [4].

Solubility:

DMSO: 48.5 mg/mL (126.17 mM), Sonication is recommended. Ethanol: 3.85 mg/mL (10.02 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

In vivo Formulation:

10% DMSO+90% Saline: 0.1 mg/mL (0.26 mM), Solution. 10% DMSO+40% PEG300+ 5% Tween 80 + 45% Saline: 4.85 mg/mL (12.62 mM), Solution.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The

formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Preparing Stock Solutions:

	1mg	5mg	10mg
1 mM	2.6015 mL	13.0076 mL	26.0152 mL
5mM	0.5203 mL	2.6015 mL	5.203 mL
10mM	0.2602 mL	1.3008 mL	2.6015 mL
50mM	0.052 mL	0.2602 mL	0.5203 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density

Reference:

Halder SK, et al. A specific inhibitor of TGF-beta receptor kinase, SB-431542, as a potent antitumor agent for human cancers. *Neoplasia*. 2005 May;7(5):509-21.

Chen X, Wang P, Qiu H, et al. Integrative epigenomic and transcriptomic analysis reveals the requirement of JUNB for hematopoietic fate induction. *Nature Communications*. 2022, 13(1): 1-16

Liu B, Li C, Bo Y, et al. Let-7f-5p Regulated by Hsa_circ_0000437 Ameliorates Bleomycin-Induced Skin Fibrosis. *Journal of Cellular Biochemistry*. e30629.

Sex-biased gene expression during neural differentiation of human embryonic stem cells

Beauvericin suppresses the proliferation and pulmonary metastasis of osteosarcoma by selectively inhibiting TGFBR2 pathway

Duan F, Huang R, Zhang F, et al. Biphasic modulation of insulin signaling enables highly efficient hematopoietic differentiation from human pluripotent stem cells. *Stem Cell Research & Therapy*. 2018 Jul 27;9(1):205

Hjelmeland MD, et al. SB-431542, a small molecule transforming growth factor-beta-receptor antagonist, inhibits human glioma cell line proliferation and motility. *Mol Cancer Ther*. 2004 Jun;3(6):737-45.

Chambers SM, et al. Highly efficient neural conversion of human ES and iPS cells by dual inhibition of SMAD signaling. *Nat Biotechnol*. 2009 Mar;27(3):275-80. doi: 10.1038/nbt.1529. Epub 2009 Mar 1. Erratum in: *Nat Biotechnol*. 2009 May;27(5):485.

Bao, Shixiang, et al. TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma. *Frontiers in Oncology*. 11 (2021): 2516.

Bao, Shixiang, et al. TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma. *Frontiers in Oncology*. 11 (2021): 2516.

Sato M, et al. Differential Proteome Analysis Identifies TGF-β-Related Pro-Metastatic Proteins in a 4T1 Murine Breast Cancer Model. *PLoS One*. 2015 May 18;10(5):e0126483.

Davies MR, et al. TGF-β Small Molecule Inhibitor SB431542 Reduces Rotator Cuff Muscle Fibrosis and Fatty Infiltration By Promoting Fibro/Adipogenic Progenitor Apoptosis. *PLoS One*. 2016 May 17;11(5):e0155486.

Bao, Shixiang, et al. TGF-β1 Induces Immune Escape by Enhancing PD-1 and CTLA-4 Expression on T Lymphocytes in Hepatocellular Carcinoma. *Frontiers in Oncology*. 11 (2021): 2516.

Fu J, Jiang L, Yu B, et al. Generation of a Human iPSC Line CIBi010-A with a Reporter for ASGR1 Using CRISPR/Cas9. *Stem Cell Research*. 2022: 102800

Ma J, et al. Growth differentiation factor 11 improves neurobehavioral recovery and stimulates angiogenesis in rats subjected to cerebral ischemia/reperfusion. *Brain Res Bull*. 2018 Feb 9;139:38-47.

Duan F, Huang R, Zhang F, et al. Biphasic modulation of insulin signaling enables highly efficient hematopoietic

differentiation from human pluripotent stem cells[J]. Stem cell research & therapy. 2018 Jul 27;9(1):205.

Liu S, Yan X, Guo J, et al.Periodontal ligament-associated protein-1 knockout mice regulate the differentiation of osteoclasts and osteoblasts through TGF- β 1/Smad signaling pathway.Journal of Cellular Physiology.2023

Xiong, Yanlu, et al. TFAP2A potentiates lung adenocarcinoma metastasis by a novel miR-16 family/TFAP2A/PSG9/TGF- β signaling pathway. . Cell Death & Disease . 12.4 (2021): 1-13.

Ying J, Wang P, Jin X, et al.TGF- β 1 Mediates the EndoMt in High Glucose-Treated Human Retinal Microvascular Endothelial Cells.Seminars in Ophthalmology. Taylor & Francis.2024: 1-8.

Yang Y, Suo N, Cui S, et al.Trametinib, an anti-tumor drug, promotes oligodendrocytes generation and myelin formation.Acta Pharmacologica Sinica.2024: 1-13.

Chen F, Gao Q, Wei A, et al. Histone deacetylase 3 aberration inhibits Klotho transcription and promotes renal fibrosis[J]. Cell Death & Differentiation. 2020: 1-12.